Dr.Chang is a Urologic Oncologist with a clinical and research focus on prostate cancer. Currently, he is an Instructor in Surgery at Harvard Medical School, and Director of the Prostate Cancer Care Center at the Beth Israel Deaconess Medical Center. He is a leader in the assessment and management of health-related quality of life (HRQOL) using patient-reported outcomes (PROs), and has a particular interest in the adaptation and implementation of PROs to directly improve patient evaluation and communication in clinical practice. He developed the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) with the goal of allowing HRQOL to be assessed using PROs at the point of care. He is a co-leader of the PROST-QA consortium, a multicenter, prospective cohort of 1,201 men treated for localized prostate cancer followed longitudinally for clinical and HRQOL outcomes. His prostate cancer outcomes research focuses on investigating the factors predicting HRQOL after prostate cancer treatment and evaluating HRQOL in the advanced disease setting. As a practicing minimally invasive urologic surgeon, he also studies HRQOL and surgical outcomes following minimally invasive kidney cancer and bladder cancer surgery.